ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon

Welcome to our new website

As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.

Health Technology

Astellas Pharma, Inc.

  • 1,877.00 JPY
  • -75.00
  • -3.84%
  • Japan
    Sep 18, 2018
  • Ticker
    TKS(4503)
  • Prev. close
    1,952
  • Market cap (JPY)
    3,864.61B
  • Market cap (USD)
    34,522.44M
  • Shares
    1,979.82M

In the news

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue1,300.31B11,732.27M
Gross Profit970,228M8,754.00M
Operating income271,241M2,447.30M
Income before tax218,113M1,967.95M
Net income164,679M1,485.83M
EBITDA336,104M3,032.54M
Diluted EPS81.020.73
Dividends Per Share360.32
Total Assets1,858.20B17,472.54M
Total liabilities583,608M5,487.61M
Total equity1,268.28B11,925.61M
Operating cash flow314,463M2,837.28M
Currency in JPYCurrency in USD

Historical Data

JPY | USD
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,139.90B 1,247.25B 1,372.70B 1,311.66B 1,300.31B
Gross Profit 773,281M 875,398M 994,723M 955,325M 970,228M
Operating income 184,803M 216,283M 269,638M 276,419M 271,241M
Income before tax 120,524M 189,466M 263,013M 281,769M 218,113M
Net income 90,874M 135,856M 193,687M 218,701M 164,679M
EBITDA 249,107M 281,757M 338,826M 340,210M 336,104M
Diluted EPS 40.39 61.40 89.62 103.55 81.02
Dividends Per Share 27 30 32 34 36
Total Assets 1,653.10B 1,793.57B 1,799.33B 1,814.07B 1,858.20B
Total liabilities 384,632M 475,662M 540,129M 540,614M 583,608M
Total equity 1,268.47B 1,317.91B 1,259.20B 1,271.81B 1,268.28B
Operating cash flow 217,579M 189,977M 316,534M 237,230M 314,463M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 11,379.57M 11,353.53M 11,431.18M 12,112.80M 11,732.27M
Gross Profit 7,719.57M 7,968.55M 8,283.53M 8,822.11M 8,754.00M
Operating income 1,844.86M 1,968.77M 2,245.40M 2,552.63M 2,447.30M
Income before tax 1,203.17M 1,724.66M 2,190.23M 2,602.04M 1,967.95M
Net income 907.18M 1,236.66M 1,612.92M 2,019.63M 1,485.83M
EBITDA 2,486.80M 2,564.77M 2,821.56M 3,141.72M 3,032.54M
Diluted EPS 0.40 0.55 0.74 0.95 0.73
Dividends Per Share 0.26 0.27 0.26 0.31 0.32
Total Assets 16,051.92M 14,955.82M 16,009.05M 16,279.92M 17,472.54M
Total liabilities 3,734.83M 3,966.32M 4,805.63M 4,851.60M 5,487.61M
Total equity 12,317.09M 10,989.50M 11,203.42M 11,413.53M 11,925.61M
Operating cash flow 2,172.06M 1,729.31M 2,635.93M 2,190.74M 2,837.28M

Valuation Measures

Mar 2018
PER19.89
ROA8.96%
ROE12.96%
Operating margin20.85%
Profit margin12.66%

Key executives

  • President, CEO & Representative Director: Kenji Yasukawa
  • Chief Financial Officer: Chikashi Takeda
  • General Manager-Pharmaceutical Technology: Mitsunori Matsuda
  • Executive Officer & Head-Compliance: Fumiaki Sakurai
  • Senior Vice President-Corporate Communications: Stig Ogata

Shareholders

  • Nomura Asset Management Co., Ltd. (5.0%)
  • BlackRock Fund Advisors (4.0%)
  • Nippon Life Insurance Co. (3.2%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • BlackRock Japan Co., Ltd. (2.6%)
  • The Vanguard Group, Inc. (2.4%)
  • Astellas Pharma, Inc. (2.1%)
  • Daiwa Asset Management Co. Ltd. (2.1%)
  • Norges Bank Investment Management (1.4%)
  • International Value Advisers LLC (1.4%)

Contact Details

  • Website:http://www.astellas.com
  • Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
  • Phone: +81.3.3244.3000

Related Companies

  • Astellas Pharma, Inc. /Agensys Research Facilities/
  • Astellas Pharma, Inc. /16 Long Listed Products/
  • Astellas Farma Colombia
  • Astellas Pharma Director Incentive Plan
  • Astellas Pharma, Inc. /Kiyosu Plant/
  • Quethera Ltd.
  • PT Astellas Pharma Indonesia
  • Astellas Pharma ZAO
  • Astellas Pharma ilac Ticaret ve Sanayi AS
  • Astellas Pharma Hong Kong Co. Ltd.
  • Astellas Pharma India Pvt Ltd.
  • Astellas Pharma Thailand Co. Ltd.
  • Astellas Pharma Australia Pty Ltd.
  • Astellas Pharma Singapore Pte Ltd.
  • Astellas Pharma Tech Co., Ltd.
  • Mitobridge, Inc.
  • Astellas Pharma China, Inc.
  • Perseid Therapeutics LLC
  • GPDC Partnership
  • Astellas Pharma Philippines, Inc.
  • Astellas Pharma Co. Ltd.
  • Astellas Pharma Canada, Inc.
  • Fujisawa Taiwan Co. Ltd.
  • Astellas Pharma SARL
  • Astellas Pharma Netherlands
  • Yamanouchi Health & Beauty Co. Ltd.
  • Yabrofarma Lda.
  • Fujisawa Ireland Ltd.
  • Astellas Pharma Korea, Inc.
  • Yamanouchi USA, Inc.

Competitors

  • YungShin Global Holding Corp.
  • Coland Holdings Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • RedHill Biopharma Ltd.
  • Ipsen SA
  • Galapagos NV
  • Pieris Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals Inc
  • Antares Pharma, Inc.
  • ArQule, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • BioLineRX Ltd.
  • Compugen Ltd.
  • Cidara Therapeutics, Inc.
  • Constellation Pharmaceuticals, Inc.
  • ESSA Pharma Inc
  • Sophiris Bio Inc.
  • Veloxis Pharmaceuticals A/S
  • Matinas BioPharma Holdings, Inc.
  • GTx, Inc.
  • Xenon Pharmaceuticals Inc.
  • Melinta Therapeutics, Inc.
  • Kura Oncology, Inc.
  • Molecular Templates, Inc.
  • Cellular Biomedicine Group, Inc.
  • ImmunoGen, Inc.
  • Sonoma Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • SCYNEXIS, Inc.
  • Dermira Inc

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.

Last Updated on 18 Sep, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media